Multiple studies spotlight novel approaches and biomarkers to combat hepatocellular carcinoma (HCC). Research shows the efficacy of combining transarterial chemoembolization (TACE) with targeted therapies post liver transplantation to improve survival. New findings identify circulating tumor cells as indicators of microvascular invasion and recurrence risk. Additionally, basal metabolic rate has emerged as an influential factor in liver cancer progression, while novel postbiotic therapies show promise for advanced alcohol-related liver disease management.